CARB-X Archives • Page 2 of 3 • AMR.Solutions

CARB-X 2019: Calls announced covering non-traditionals, vaccines-biologics, diagnostics, and direct-acting small molecules

Aside: There is now an application link for the Mar 2020 Antibacterial R&D GRC meeting. See calendar listing below my signature! Dear All: CARB-X this week announced its 2019 calls for proposals (link). There are four application rounds: Non-traditional approaches: Funding Round 1 will be open for Expressions of Interest June 3 – June 10, 2019, 5 PM

3 May 2019 No Comments

CARB-X receives $50m from UK & Gates; Session at BIO on antibiotic reimbursement; PLOS opens an AMR Channel; CDD-sponsored SAR webinar

Dear All: There has been tremendously exciting activity in parallel with this week’s World Health Assembly! Here’s the list… CARB-X has announced this week that the Bill & Melinda Gates Foundation and the UK government will contribute $25 million and £20 million ($26.9 million), respectively, over the next 3 years. With this new inflow of $50m in committed funds,

23 May 2018 No Comments

Summary, slides, & video from the CARB-X + GARDP Bootcamps, 5-8 Sep 2017 ASM-ESCMID Conference

This note was updated on 12 Jan 2018 to provide links to the videos from the bootcamp sessions. Dear All: GARDP + CARB-X have this week hosted Antibiotic Bootcamps #1, #2, and #3 at the ASM-ESCMID conference on antibiotic R&D. There were nearly 350 people registered for the full meeting with good attendance at each Bootcamp.

6 September 2017 No Comments

CARB-X at work! New funding round, new job opportunities

Dear All, Two things on a Friday afternoon: First,CARB-X Funding Round 4 will be open from 12-19 Nov 2019 for Expressions of Interest (EOIs). This round is very focused and seeks only applications for new classes and/or new targets in early development phases (hit-to-lead through Phase 1) targeting a specific list of Gram-negative pathogens (see link,

25 October 2019 No Comments

Powered by CARB-X: Portfolio expansion announced today!

Dear All: CARB-X has today announced funding of 7 more companies, bringing the total funded portfolio to 17 potential new therapies (or preventatives) and 1 novel point-of-care diagnostic (see graphic above). Befitting the international nature of those of you who read my occasional notes (see map just below), there are now funded companies in 6 countries (US, UK, France,

25 July 2017 No Comments

Building momentum for delinked incentives: Key upcoming webinars

Dear All, A brief note today as I am traveling (yes, really … first time in almost 18 months) but wanted to share these 3 important upcoming meetings. The theme I expect to hear running through them all is that (i) innovation is possible (the CARB-X Year 5 report is amazing!), (ii) new antibiotics must both

17 October 2021 No Comments

CARB-X Application Round #3 goes live!

Dear All: The wait is over — CARB-X has today released a call for new applications! The call has an interesting 2-round structure and you’ll need to study carefully both the press release and the supplemental details document to understand where your program would fit. Here’s my summary: Round 1: Submission window for Expressions of Interest: 22-29 March 2018 Scope: Restricted

20 February 2018 No Comments

More jobs! CARB-X also has openings

Dear All: Building on my recent note about a search for the G20 secretariat lead, we now have CARB-X getting into job creation mode by posting 8 positions across 5 different job openings: Accelerator Lead: coordinates the work of the growing accelerator network for all CARB-X-funded companies. Support Team Lead (three positions): takes responsibility for managing the full range of

7 February 2018 No Comments

CARB-X funding round #1, SDRI 2017, & Antibiotic-tainted seafood

Dear All: Just in case you missed the 30 March annoucement, see at right a snapshot of the first 11 Powered by CARB-X funded companies. Initial funding is $24m, with potentially a further $24m if the companies hit their milestones. With the funds provided by the companies themselves, the total potential investment is $75m. This is just the start:

2 April 2017 No Comments

CARB-X is seeking additional accelerators to expand support for its pipeline

Dear All: It is exciting to see that CARB-X today announced that it is seeking to partner with up to 6 additional accelerator organizations to expand its drug development and business support for its growing pipeline of early development antibacterial research projects. The Powered by CARB-X portfolio currently has 22 active projects in its pipeline, with more project announcements

23 January 2018 No Comments

AMR.Solutions

CARB-X